Mingen Lin
MOE Key Laboratory Of Metabolism And Molecular Medicine
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Correction: Dimethyl fumarate promotes the degradation of HNF1B and suppresses the progression of clear cell renal cell carcinoma.
Journal: Cell death & disease
Published: May 19, 2025
TET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma.
Journal: Cell death & disease
Published: November 07, 2024
d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity.
Journal: Cancer letters
Published: September 29, 2023
GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer.
Journal: Heliyon
Published: August 03, 2023
New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer.
Journal: Molecular therapy oncolytics
Published: May 22, 2023
TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential.
Journal: Cell discovery
Published: January 12, 2023
Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma.
Journal: The Journal of clinical investigation
Published: August 15, 2022
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 12, 2022
TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Journal: Cancer research
Published: September 04, 2021
Showing 1-12 of 12
Last Updated: 09/26/2026